

Supplement Documents for Results FY2008

Astellas Pharma Inc.

- Financial Results of FY2008
- Pipeline list

Cautionary statement regarding forward-looking information

This material includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, the pricing and product initiatives of competitors, the inability of the company to market existing and new product effectively, interruptions in production, infringement of the company's intellectual property rights and the adverse outcome of material litigation.

Consolidated Results

1. Detailed Information from Operating Results

	billion yen (rounddown under 0.1 billion yen)				Forecasts		Forecasts	
	Mar 08 Full Year	Mar 09 Full Year	Change	Change (%)	Mar 10 2Q	Change (%)	Mar 10 Full Year	Change (%)
Net Sales	972.5	965.6	-6.8	-0.7%	486.0	-1.5%	968.0	0.2%
Cost of Sales	279.3	264.4	-14.9	-5.3%				
Ratio to Net Sales	28.7%	27.4%						
Gross Profit	693.2	701.2	8.0	1.2%				
SG&A	417.3	450.8	33.5	8.0%				
Ratio to Net Sales	42.9%	46.7%						
R&D	134.4	159.0	24.5	18.3%	81.0	2.9%	169.0	6.3%
SG&A excluding R&D	282.8	291.8	8.9	3.2%				
Advertising and Sales Promotion	83.0	84.8	1.7	2.1%				
Salaries, Bonuses and Allowances	120.1	115.1	-5.0	-4.2%				
Other	79.6	91.8	12.2	15.3%				
Operating Income	275.9	250.3	-25.5	-9.2%	117.0	-10.9%	215.0	-14.1%
Ratio to Net Sales	28.4%	25.9%			24.1%		22.2%	
Non-operating Income	24.8	22.2	-2.6	-10.6%				
Exchange Gain	-	9.2	9.2	-				
Equity in losses of affiliates	7.9	-	-7.9	-				
Non-operating Expenses	16.5	1.1	-15.3	-92.8%				
Exchange Loss	14.8	-	-14.8	-				
Ordinary Income	284.1	271.4	-12.7	-4.5%	119.0	-19.4%	219.0	-19.3%
Ratio to Net Sales	29.2%	28.1%			24.5%		22.6%	
Special Gains	13.3	1.9	-11.4	-85.7%				
Gain on sales of fixed assets	11.3	1.3	-10.0	-88.3%				
Special Losses	28.7	10.6	-18.0	-62.9%				
Loss on sale and disposal of fixed assets	2.1	3.0	0.9	43.1%				
Loss on impairment of fixed assets	9.3	1.3	-7.9	-85.6%				
Expenses for integration and closure of Business Bases	3.3	-	-3.3	-				
Loss on devaluation of investments securities	-	1.9	1.9	-				
Special Retirement Benefits	12.9	2.5	-10.4	-80.5%				
Other	0.9	1.7	0.7	80.2%				
Income before Income Taxes	268.7	262.6	-6.0	-2.3%				
Income Taxes	89.1	89.6	0.4	0.5%				
Minority Interests	2.1	2.0	-0.0	-3.2%				
Net Income	177.4	170.9	-6.4	-3.6%	73.0	-19.7%	135.0	-21.0%
Ratio to Net Sales	18.2%	17.7%			15.0%		13.9%	

2. Segment Information by Business

billion yen

		Mar 08 Full Year	Mar 09 Full Year	Change	Change (%)
Sales	Consolidated	972.5	965.6	-6.8	-0.7%
	Pharmaceutical	971.5	964.6	-6.8	-0.7%
	Ratio to Net Sales	99.9%	99.9%		
	Other	1.0	1.0	-0.0	-5.2%
	Ratio to Net Sales	0.1%	0.1%		

3. Overseas Sales

billion yen

		Mar 08 Full Year	Mar 09 Full Year	Change	Change (%)
Overseas Sales		489.5	468.9	-20.5	-4.2%
	Ratio to Net Sales	50.3%	48.6%		
North America		247.1	235.0	-12.1	-4.9%
	Ratio to Net Sales	25.4%	24.3%		
Europe		195.6	180.3	-15.2	-7.8%
	Ratio to Net Sales	20.1%	18.7%		
Asia and others		46.8	53.5	6.7	14.4%
	Ratio to Net Sales	4.8%	5.6%		

Forecasts

Forecasts

Mar 10 2Q	Change (%)	Mar 10 Full Year	Change (%)
229.6	-8.4%	444.4	-5.2%
47.3%		45.9%	

4. Segment Information by Region

		billion yen			
		Mar 08	Mar 09	Change	Change
		Full Year	Full Year		(%)
Sales		972.5	965.6	-6.8	-0.7%
	Japan	505.5	510.4	4.9	1.0%
	Ratio to Net Sales	52.0%	52.9%		
	North America	194.5	188.8	-5.6	-2.9%
	Ratio to Net Sales	20.0%	19.6%		
	Europe	244.6	239.1	-5.5	-2.3%
	Ratio to Net Sales	25.2%	24.8%		
	Asia	27.8	27.2	-0.6	-2.2%
	Ratio to Net Sales	2.9%	2.8%		
Operating Income		275.9	250.3	-25.5	-9.2%
	Japan	176.0	175.5	-0.4	-0.3%
	Ratio to Net Sales	63.8%	70.1%		
	North America	56.3	32.8	-23.4	-41.7%
	Ratio to Net Sales	20.4%	13.1%		
	Europe	41.0	39.8	-1.2	-2.9%
	Ratio to Net Sales	14.9%	15.9%		
	Asia	2.7	3.3	0.6	22.3%
	Ratio to Net Sales	1.0%	1.3%		
	Eliminations	-0.2	-1.2	-0.9	

Forecasts		Forecasts	
Mar 10	Change	Mar 10	Change
2Q	(%)	Full Year	(%)
486.0	-1.5%	968.0	0.2%
256.4	2.3%	523.6	2.6%
52.7%		54.1%	
101.4	5.9%	202.4	7.2%
20.9%		20.9%	
115.0	-13.0%	215.0	-10.1%
23.7%		22.2%	
13.2	-9.1%	27.0	-0.9%
2.7%		2.8%	
117.0	-10.9%	215.0	-14.1%

5. Exchange Rate

	yen			
	Mar 08 Ave	Mar 09 Ave	Mar 08 End	Mar 09 End
Yen/USD	114	101	100	98
Yen/EUR	162	143	158	130

Forecasts

Mar 10 2Q
100
130

Forecasts

Mar 10 Full Year
100
130

6. Per Share Information

	Mar 08 Full Year	Mar 09 Full Year
The number of share issued (thousand)	518,964	503,964
Treasury Stock (thousand)	20,881	33,948
The number of share issued after deducting Treasury Stock	498,083	470,016
Earnings per share (yen)	349.89	356.11
Dividend per share (yen)	110	120
Return on Equity (%)	16.1%	16.0%
Dividend on Earnings (%)	5.0%	5.4%

Mar 10 2Q
155.31
60

Mar 10 Full Year
287.22
125

7. Research and Development Expenses

	billion yen			
	Mar 08 Full Year	Mar 09 Full Year	Change	Change (%)
Research and Development	134.4	159.0	24.5	18.3%
Ratio to Net Sales	13.8%	16.5%		

Mar 10 2Q	Change (%)	Mar 10 Full Year	Change (%)
81.0	2.9%	169.0	6.3%
16.7%		17.5%	

8. Addition to Property, Plant and Equipment

	billion yen			
	Mar 08 Full Year	Mar 09 Full Year	Change	Change (%)
Addition to Property, Plant and Equipment				
Consolidated	26.4	37.6	11.1	42.2%
Parent	15.8	24.5	8.6	54.6%
Depreciation (Tangible)				
Consolidated	22.5	24.7	2.1	9.7%
Parent	8.6	12.5	3.9	45.6%
Depreciation (Intangible)				
Consolidated	12.6	10.6	-1.9	-15.3%
Parent	5.2	4.5	-0.7	-13.7%

Mar 10 Full Year	Change (%)
37.7	0.1%
30.2	22.2%
9.3	-13.0%

- Amortization of goodwill (not included in depreciation (intangible))

1.7 7.4

9.4

9. Employee

	Mar 08 Full Year	Mar 09 Full Year
Total	13,666	14,261
Japan	7,453	7,522
North America	2,084	2,318
Europe	3,177	3,390
Asia	952	1,031
Total Medical Representatives	5,000	5,150

10. Shareholders

	Mar 08 Full Year	Mar 09 Full Year
Banks	34.1%	36.2%
Securities	3.7%	1.8%
Other companies	3.8%	3.9%
Foreign companies	46.6%	43.2%
Individuals and others	7.7%	8.2%
Treasury Stock	4.0%	6.7%

11. Detailed Pharmaceutical Segment Information

1) Consolidated sales of major products

	billion yen				Forecasts		Forecasts	
	Mar 08 Full Year	Mar 09 Full Year	Change	Change (%)	Mar 10 2Q	Change (%)	Mar 10 Full Year	Change (%)
Prograf	203.0	201.0	-1.9	-1.0%	99.1	-5.1%	192.3	-4.4%
Sales by Astellas	198.2	194.7	-3.4	-1.8%	95.5	-5.5%	186.1	-4.4%
Japan	24.6	28.5	3.9	16.0%	16.5	19.4%	34.8	21.9%
North America	97.2	88.8	-8.3	-8.6%	43.8	-2.2%	82.2	-7.5%
Europe	65.3	66.0	0.7	1.1%	29.5	-19.0%	57.4	-13.1%
Advagraf	1.1	6.3	5.1	440.6%				
Asia	11.0	11.2	0.1	1.7%	5.8	-5.1%	11.7	3.6%
Exports to third parties (Europe)	4.8	6.3	1.4	30.9%	3.6	6.5%	6.2	-2.3%
Harnal	122.4	116.6	-5.7	-4.7%	57.0	-6.0%	103.8	-11.1%
Sales by Astellas	75.7	70.0	-5.6	-7.5%	32.2	-12.3%	65.1	-7.0%
Japan	37.5	35.6	-1.9	-5.1%	17.7	0.6%	35.5	-0.4%
Europe	29.5	25.7	-3.7	-12.7%	10.5	-28.0%	21.5	-16.7%
Capsule	12.3	9.2	-3.0	-24.6%	3.0	-43.2%	6.5	-29.8%
Omic OCAS	17.2	16.5	-0.7	-4.1%	7.4	-19.3%	15.0	-9.4%
Asia	8.2	8.1	-0.0	-0.1%	3.8	-11.4%	7.7	-5.9%
Bulk and Royalties (Europe)	46.7	46.6	-0.1	-0.3%	24.8	3.7%	38.7	-17.1%
Vesicare	60.1	71.4	11.2	18.8%	40.1	10.4%	84.2	17.8%
Japan	13.5	19.0	5.5	40.9%	10.9	23.5%	22.8	19.9%
North America	27.7	31.0	3.3	12.0%	18.3	14.9%	38.4	23.6%
Europe	18.5	20.6	2.0	11.1%	10.3	-7.2%	21.9	6.2%
Asia	0.3	0.7	0.3	112.0%	0.5	38.2%	1.1	50.3%
Funguard/Mycamine	17.8	17.5	-0.3	-1.9%	10.1	20.9%	20.5	17.3%
Japan	12.8	11.6	-1.1	-9.0%	5.9	0.6%	11.9	2.0%
North America	4.7	5.1	-0.4	8.7%	3.4	54.1%	6.6	29.3%
Europe	—	0.1	0.1	—	0.4	—	1.1	857.3%
Asia	0.2	0.5	0.2	100.9%	0.4	58.0%	0.8	44.7%
Protopic	16.4	16.1	-0.3	-2.0%	8.1	-4.9%	16.6	2.7%
Japan	2.7	2.7	-0.0	-0.2%	1.4	2.4%	2.9	5.4%
North America	8.0	7.6	-0.4	-5.5%	3.8	-4.1%	7.7	1.3%
Europe	5.2	5.2	0.0	0.7%	2.6	-10.2%	5.3	1.1%
Asia	0.4	0.5	0.0	15.3%	0.3	-0.2%	0.7	22.9%

- Sales of products in Japan are shown in a gross sales basis.

2) Consolidated Sales of Other Products

billion yen

Rx Sales in Japan <Global products>	Mar 08 Full Year	Mar 09 Full Year	Change	Change (%)
Prograf (incl. Gracaptor)	24.6	28.5	3.9	16.0%
Harnal	37.5	35.6	-1.9	-5.1%
Vesicare	13.5	19.0	5.5	40.9%
Funguard	12.8	11.6	-1.1	-9.0%
Protopic	2.7	2.7	-0.0	-0.2%

<Domestic Products>

Lipitor	97.7	95.3	-2.4	-2.5%
Micardis	62.6	64.4	1.8	2.9%
Gaster	60.9	53.0	-7.8	-12.9%
Myslee	21.5	25.7	4.2	19.5%
Seroquel	19.2	21.0	1.8	9.6%
Vaccines	15.7	17.3	1.5	9.9%
Cefzon	14.5	11.7	-2.7	-19.0%
Frاندol	12.0	11.3	-0.6	-5.6%
Luvox	11.0	10.0	-1.0	-9.1%
Celecox (launched in June 2007)	3.7	10.4	6.7	178.7%
Geninax (launched in October 2007)	3.7	6.4	2.6	71.9%
Irribow (launched in October 2008)	-	1.6	1.6	-
Total Rx Sales In Japan	478.2	491.5	13.3	2.8%

Forecasts

Forecasts

Mar 10 2Q	Change (%)	Mar 10 Full Year	Change (%)
16.5	19.4%	34.8	21.9%
17.7	0.6%	35.5	-0.4%
10.9	23.5%	22.8	19.9%
5.9	0.6%	11.9	2.0%
1.4	2.4%	2.9	5.4%

49.0	4.2%	99.0	3.9%
35.2	12.4%	71.8	11.4%
25.4	-4.8%	50.6	-4.7%
13.6	9.3%	27.8	8.0%
11.6	11.8%	22.9	8.5%
2.2	-53.7%	14.6	-15.8%
5.3	2.2%	10.8	-8.2%
5.6	-2.0%	11.1	-1.9%
5.2	0.6%	10.2	1.0%
7.0	43.7%	15.0	43.6%
3.6	87.6%	11.3	75.1%
1.2	-	3.0	78.4%
248.7	3.8%	507.8	3.3%

- Sales of products in Japan are shown in a gross sales basis.

		billion yen			
RX Sales in North America and Europe		Mar 08 Full Year	Mar 09 Full Year	Change	Change (%)
Scan* (North America)		37.6	39.3	1.6	4.5%
Lexiscan		-	9.4	9.4	-
AmBisome (North America)		7.6	6.1	-1.4	-19.0%
Vaprisol (North America)		0.9	0.7	-0.1	-18.6%
Amevive (North America)		2.2	1.7	-0.5	-24.9%
Eligard (Europe)		9.2	12.5	3.2	35.2%

* Adenoscan + Lexiscan

		billion yen			
Export Sales		Mar 08 Full Year	Mar 09 Full Year	Change	Change (%)
Cefzon	Overseas (exports to third party)	5.3	1.1	-4.1	-77.4%
Cefspan	Overseas (exports to third party)	6.4	6.0	-0.4	-6.7%

		Forecasts		Forecasts	
		Mar 10 2Q	Change (%)	Mar 10 Full Year	Change (%)
		24.3	22.6%	50.0	27.2%
		3.1	1.7%	6.2	-0.1%
		0.9	53.9%	1.4	87.4%
		0.9	-2.3%	1.9	12.2%
		6.2	-5.5%	13.5	8.0%

		Mar 10 2Q	Change (%)	Mar 10 Full Year	Change (%)
		0.6	-30.8%	1.1	-8.8%
		2.4	-38.7%	5.0	-17.2%

Sales in North America and Europe

Unit: M\$

	Mar 08 Full Year	Mar 09 Full Year	Change	Change (%)
North America				
Sales	1,702	1,878	176	10.4%
Prograf	850	884	33	3.9%
Scan*	329	390	61	18.8%
Lexiscan	-	93	93	-
AmBisome	66	61	-5	-8.0%
Protopic	70	75	5	7.5%
VESIcare	242	308	66	27.3%
Mycamine	41	51	9	23.5%
Vaprisol	7	7	-0	-7.5%
Amevive	19	16	-2	-14.6%

* Adenoscan + Lexiscan

Forecasts

Forecasts

	Mar 10 2Q	Change (%)	Mar 10 Full Year	Change (%)
Sales	1,014	12.3%	2,024	7.8%
Prograf	438	3.8%	822	-7.0%
Scan*	243	30.1%	500	27.9%
AmBisome	31	8.0%	62	0.4%
Protopic	38	1.8%	77	1.8%
VESIcare	183	21.9%	384	24.2%
Mycamine	34	63.5%	66	30.0%
Vaprisol	9	63.3%	14	88.4%
Amevive	9	3.7%	19	12.8%

Unit: M€

	Mar 08 Full Year	Mar 09 Full Year	Change	Change (%)
Europe				
Sales	1,514	1,666	151	10.0%
Harnal	472	504	32	6.8%
Sales by Astellas	182	179	-3	-1.7%
Capsule	76	64	-12	-15.2%
OCAS	106	115	8	7.9%
Bulk and Royalties	289	324	35	12.2%
Prograf	434	502	68	15.7%
Sales by Astellas	404	460	55	13.8%
Advagraf	7	44	37	508.6%
Exports to third parties	29	42	12	42.1%
Vesicare	114	143	28	25.1%
Protopic	32	36	4	13.4%
Mycamine	-	0	0	-
Eligard	57	87	29	52.2%

	Mar 10 2Q	Change (%)	Mar 10 Full Year	Change (%)
Sales	885	8.8%	1,654	-0.8%
Harnal	271	15.6%	463	-8.4%
Sales by Astellas	80	-9.9%	165	-8.1%
Capsule	23	-29.0%	50	-22.5%
OCAS	57	1.0%	115	0.0%
Bulk and Royalties	190	31.4%	297	-8.5%
Prograf	254	3.9%	488	-3.0%
Sales by Astellas	227	1.4%	441	-4.1%
Advagraf	7	31.1%	47	9.7%
Exports to third parties	27	31.1%	47	9.7%
Vesicare	79	16.2%	169	17.2%
Protopic	20	12.3%	41	11.6%
Mycamine	3	-	9	956.5%
Eligard	48	18.2%	104	19.2%

12.Consolidated Balance Sheets

Billion yen

	31-Mar-09		31-Mar-08		Change	Comments
	Amount	Composition	Amount	Composition		
Assets	1,348.4	100.0%	1,439.1	100.0%	-90.7	
Current assets	963.6	71.5%	977.2	67.9%	-13.6	
Cash on hand and in banks	267.4		248.5		18.9	
Trade notes and accounts receivable	222.9		222.0		0.9	- Cash on hand and in banks(+18.9)
Marketable securities	246.4		293.5		-47.1	Marketable securities (-47.1)
Merchandise and finished goods	80.7		65.5		15.2	- Investment securities (-68.2)
Work in process	12.5		12.3		0.1	
Raw materials and supplies	12.1		13.5		-1.3	Decrease in "cash on hand"
Deferred tax assets	67.5		68.0		-0.4	due to share buyback
Other	54.7		54.3		0.4	Decreased amount on Investment securities
Allowance for doubtful receivable	-1.0		-0.6		-0.3	includes decrease in market fair value
Fixed assets	384.8	28.5%	461.8	32.1%	-77.0	
Property, plant and equipment	181.4	13.5%	179.8	12.5%	1.5	
Buildings and structures	96.1		78.6		17.5	- Buildings and structures (+17.5)
Machinery, equipment and vehicles	23.6		26.9		-3.3	New laboratory building in Tsukuba
Tools, furniture and fixtures	16.8		17.2		-0.4	- Construction in progress (-11.5)
Land	29.1		31.2		-2.1	Shift buildings and structures
Construction in progress	13.9		25.5		-11.5	
Other	1.8		0.2		-1.6	- Goodwill (-2.9)
Intangible fixed assets	58.3	4.3%	67.9	4.7%	-9.6	Goodwill associated with Agensys
Goodwill	26.3		29.3		-2.9	Decrease due to amortization
Other	31.9		38.6		-6.6	(Increase due to milestone payment)
Investments and other assets	144.9	10.8%	214.0	14.9%	-69.0	
Investment securities	89.5		157.7		-68.2	
Deferred tax assets	46.2		39.7		6.4	
Other	9.2		16.7		-7.4	
Allowance for doubtful receivables	-0.0		-0.2		0.1	

	31-Mar-09		31-Mar-08		Change	Comments
	Amount	Composition	Amount	Composition		
Liabilities and Shareholders' Equity	1,348.4	100.0%	1,439.1	100.0%	-90.7	
Liabilities	318.2	23.6%	328.2	22.8%	-10.0	
Current liabilities	283.5	21.0%	284.5	19.8%	-0.9	- Trade notes and account payable (+19.7)
Trade notes and accounts payable	89.7		70.0		19.7	Increase mainly in Japan
Other accounts payable	91.7		107.4		-15.6	- Other accounts payable (-15.6)
Accrued expenses	52.1		56.2		-4.1	Decrease payable accounts outstanding
Accrued income taxes	39.6		38.0		1.6	for marketable securities
Accrued consumption tax	0.4		2.0		-1.6	
Deferred tax liabilities	0.8		0.0		0.7	
Accrued bonus for directors	0.1		0.1		-0.0	
Allowance for sales rebates	2.7		5.0		-2.2	
Other	6.0		5.3		0.6	
Long-term liabilities	34.6	2.6%	43.7	3.0%	-9.0	
Deferred tax liabilities	-		0.2		-0.2	
Accrued retirement benefits for employees	15.0		17.4		-2.4	
Other	19.6		26.0		-6.3	- Shareholders' equity (-51.1)
Shareholders' equity	1,030.2	76.4%	1,110.8	77.2%	-80.6	Share buyback (-123.6)
Common stock	103.0	7.6%	103.0	7.2%	-	Treasury stock (+72.1)
Additional paid-in capital	176.8	13.1%	176.8	12.3%	-	
Retained earnings	957.3	70.9%	917.2	63.7%	40.1	
Treasury stock	-155.2	-11.5%	-104.1	-7.2%	-51.1	
Unrealized holding gains on securities	10.0	0.8%	27.8	2.0%	-17.8	
Translation adjustments	-62.9	-4.7%	-10.8	-0.8%	-52.0	Translation adjustments (-52.0)
Stock acquisition rights	0.8	0.1%	0.6	0.0%	0.2	Declining due to difference between
Minority interests	0.3	0.0%	0.3	0.0%	-0.0	historical rate and closing rate